What is the
SPOT-MAS test?

AI-Powered Blood Test To Outsmart Multi-cancer

SPOT-MAS is a non-invasive, multi-cancer early detection (MCED) test that detects tumor DNA (ctDNA) circulating in the blood.

This test incorporates next-generation sequencing (NGS) and AI technologies to analyze the multiple features of ctDNA, enabling early detection for the most common and aggressive cancers from a single tube of blood^1,2.

01

02

03

(1) Nguyen, L.H.D. et al. Prospective validation study: a non-invasive circulating tumor DNA-based assay for simultaneous early detection of multiple cancers in asymptomatic adults. BMC Med 23, 90 (2025). doi:10.1186/s12916-025-03929-x
(2) These 10 cancer types accounted for 56.2% of total new incidences and 59.9% of total mortality (WHO GLOBOCAN South-East Asia Report, 2022)

Brochure:

Patient Guiding Handbook 5.17 MB 962 downloads

Spot early signals of 10 common and aggressive cancers using next generation of ctDNA...

Download

Healthcare Professional Handbook 18.90 MB 859 downloads

Spot early signals of common and aggressive cancers using next-generation of ctDNA...

Download

Find out more

How does SPOT-MAS test work?

What is ctDNA technology?

Cells from all organs carry DNA. Throughout their life cycle, cells release fragments of their DNA into the bloodstream. Examining these DNA fragments can provide valuable clinical insights.

cfDNA (cell–free DNA): DNA fragments released passively from cells into bloodstream.

Since 2011, cfDNA sequencing technology has been used to detect genetic abnormalities of the fetus through the collection of pregnant women blood. This test is known as Non–invasive Prenatal Testing (NIPT).

ctDNA (circulating tumor DNA): cell–free DNA released from tumor cells. Tumor cells release ctDNA actively with multiple features significantly different with cfDNA.

Following a similar concept, ctDNA technology is clinical applied to detect and examine tumor DNA in the blood. This enables early detection of cancer for healthy individuals, as well as profiling and tracking tumor progress in cancer patients.

BENEFITS OF ADDING SPOT-MAS TO YOUR SCREENING PLAN

Early Detection

The potential to identify cancer signals at an early stage.

Efficiency

Capability to test for cancers that do not have recommended screenings to improve patient outcomes.

Convenience

One single blood draw during a healthcare visit.

High Accuracy

High specificity limits false positive and unnecessary work–up.

(1) Nguyen, et. al. (2025) Prospective validation study: a non-invasive circulating tumor DNA-based assay for simultaneous early detection of multiple cancers in asymptomatic adults. BMC Med 23, 90. https://doi.org/10.1186/s12916-025-03929-y
(2) Sekiguchi, M., & Matsuda, T. (2020). Limited usefulness of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for gastrointestinal and whole-body cancer screening. Scientific Reports, 10(1), 18202–18202. https://doi.org/10.1038/s41598-020-75319-8

SPOT-MAS 10 outperforms traditional biochemical markers (CEA and CA19-9)^{1, 2}

7- 7 x

higher sensitivity^1,2

10- 10 x

higher positive predictive value (PPV)^{1, 2}

Why should we care?

Status of 10 common and AGGRESSIVE cancers

Mortality

10 cancer types

Breast
Lung
Colorectum
Stomach*
Liver-Biliary tract*
Ovary*
Pancreas*
Esophagus*
Endometrium*
Head & Neck*

*7/10

Cancer types that currently have no standard–of–care screening program available.

The WHO GLOBOCAN South–East Asia Report (2022) tracks the incidences of more than 3,000 new cases a day, spanning a total of 32 reported cancer types⁽¹⁾. Remarkably, 10 types of cancer, accounted for 62.14% of total new incidences and 65.8% of total mortality.

Only three among them (Breast, Lung, Colorectum) have established screening programs. The need for early–stage screening for more cancer types is crucial, given the rising incidence of cancers. Early detection can significantly improve survival rates and save lives.

(1) WHO – GLOBOCAN 2022. South–Eastern Asia

The need for early detection

5–year survival rate percentage**

Early detection is key in the fight against cancer.  It not only increases the chances of successful treatment but also significantly improves the quality of life for patients.

Common cancer types like breast or colorectum have >90% survival rate if detected early⁽²⁾. However, more than 70% of cancers in low–income and middle–income Asian countries are diagnosed in late stage ⁽³⁾.

Main reasons for late detection:

People with no obvious signs of cancer  do not go for early cancer screening.
Only few cancers types have recommended screening.
Cancer symptoms mostly occur  at late stage.

Late–stage diagnosis leads to⁽⁴⁾:

5x higher mortality rate within 12 months.
50% higher chance of financial catastrophe.

(2) Statistics adapted from the American Cancer Society’s (ACS) publication, Cancer Facts & Figures 2022 and Cancer Facts & Figures 2021; the ACS website; and the International Agency for Cancer Research website.
(3) Sankaranarayanan, R., Ramadas, K., Qiao, Y., 2014. Managing the changing burden of cancer in Asia. BMC Med 12, 3.
(4) ACTION (Asean CosTs in Oncology) STUDY, Singapore 2020.

What should we do to improve early detection?

Hereditary & Familial

25 -30% ⁽¹⁾ attributed to all cancers

Occurred mutations

70% ⁽¹⁾ attributed to all cancers

(1) Garber J.E., Offit K. Hereditary Cancer Predisposition Syndromes. J. Clin. Oncol. 2005;23:276–292